CALGARY, AB, April 30, 2025 /CNW/ - Willow Biosciences Inc. (the "Company") (TSX: WLLW) (OTC-BB:CANSF) announces the completion today of the sale (the "Transaction") of its wholly-owned operating subsidiary, Epimeron USA, Inc., to the U.S. subsidiary of Mycofeast Ltd., a privately-held, arms-length entity based in the United Kingdom (the "Purchaser"), pursuant to the terms of a share purchase agreement dated March 14, 2025 (the "Share Purchase Agreement"), between the Company and the Purchaser.
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.